Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00007033|
Recruitment Status : Completed
First Posted : December 7, 2000
Last Update Posted : January 22, 2009
I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.
|Condition or disease||Intervention/treatment||Phase|
|Alagille Syndrome Cholestasis Biliary Atresia||Drug: magnesium gluconate Drug: magnesium sulfate||Not Applicable|
Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at 3-6 months.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||25 participants|
|Study Start Date :||October 2000|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00007033
|United States, Ohio|
|Children's Hospital Medical Center - Cincinnati|
|Cincinnati, Ohio, United States, 45229-3039|
|Study Chair:||James Heubi||Children's Hospital Medical Center, Cincinnati|